SARAH NOBLE: Open Payments
NPI 1366646101 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,038 in 47 payments from 11 companies in 2025. Trend: 2023 $1,501 · 2024 $285 · 2025 $1,038
Food & beverage: $1,038
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 9 | $208 |
| Janssen Pharmaceuticals, Inc | 6 | $151 |
| Teva Pharmaceuticals USA, Inc. | 6 | $143 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $138 |
| Otsuka America Pharmaceutical, Inc. | 7 | $136 |
| ABBVIE INC. | 4 | $77 |
| Alkermes, Inc. | 2 | $52 |
| E.R. Squibb & Sons, L.L.C. | 2 | $52 |
| Neurocrine BioSciences, Inc. | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
Products named: FANAPT, INVEGA SUSTENNA, CAPLYTA, AUSTEDO XR, REXULTI, VRAYLAR, ABILIFY ASIMTUFII, ARISTADA.
Industry payments across PA — which companies pay providers there.
